Synflorix

Type: Keyphrase
Name: Synflorix
First reported Jul 23 2014 - Updated Jul 24 2014 - 1 reports

Half Yearly Report

Total Group turnover for Q2 2014 declined 4% to £5,561 million. Pharmaceuticals and Vaccines turnover fell by 4%. Pharmaceuticals turnover declined 6% as growth in Emerging Markets, Europe and ViiV Healthcare was more than offset by lower sales in the ... [Published TrustNet - Jul 23 2014]
First reported Apr 23 2014 - Updated Apr 23 2014 - 1 reports

Nigeria, India out of purview

Mumbai, April 22: GlaxosmithKline Plc has deliberately left India and Nigeria out of the ambit of the new global joint venture that GSK and Novartis are forming for their consumer healthcare business. It chose to do so because they were the only two countries ... [Published Calcutta Telegraph - Apr 23 2014]
First reported Apr 19 2014 - Updated Apr 19 2014 - 1 reports

GSK sales impacted with new price control regime & boycott of stockists

The new price control regime and boycott of stockists coupled with supply constraints domestically and overseas have badly impacted the GlaxoSmithKline (GSK) results towards the end of the third quarter and bulk of the fourth quarter.  Profits were impacted ... [Published PharmaBiz - Apr 19 2014]
First reported Feb 18 2014 - Updated Feb 19 2014 - 1 reports

Human medicines European public assessment report (EPAR): Synflorix, pneumococcal polysaccharide conjugate vaccine (adsorbed), Revision: 8, Authorised

Entities: Synflorix, Vaccine
First reported Feb 05 2014 - Updated Feb 05 2014 - 1 reports

Final Results

Total Group turnover for Q4 2013 was £6,906 million, up 5%, with growth across all geographic regions except Europe, which was down 2%. Disposals did not materially affect the reported growth rate for the Group in the quarter. Pharmaceuticals and Vaccines ... [Published TrustNet - Feb 05 2014]

Quotes

Says Hasit Joshipura, managing director, GSK, "Besides this, the mass specialty business recorded a market competitive growth in the prescriber base which has resulted in benefits to patients with Augmentin, an antibiotic used to treat bacterial infections, such as sinusitis, pneumonia and bronchitis gaining significantly in market share. To address health concerns in hypothyroidism, two additional forms of Eltroxin have also been launched coupled with an awareness campaign on congenital hypothyroidism."
...GSK chief executive officer Sir Andrew Witty said the location of the new factory is yet to be finalized, but that the lead site is in Bangalore. "GSK is a long-standing investor in India and we fully support the Government in their efforts to increase access to affordable medicines and to improve healthcare. This new facility will substantially increase the capacity of our manufacturing base and enable us to bring more medicines to the people of India" said Sir Andrew
...Organization to be the only public health measure likely to have any significant impact on the incidence of pneumococcal pneumonia," Breuer said. "Today's CHMP positive opinion takes us a step closer to offering greater protection to children against this disease. "We look forward to the final decision of the European Commission and hope to make Synflorix available to more children in Europe." Final decision from the European Commission is expected during the fourth quarter of 2013."

More Content

All (10) | News (8) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
Half Yearly Report [Published TrustNet - Jul 23 2014]
Nigeria, India out of purview [Published Calcutta Telegraph - Apr 23 2014]
GSK sales impacted with new price control regim... [Published PharmaBiz - Apr 19 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 18 2014]
Final Results [Published TrustNet - Feb 05 2014]
GlaxoSmithKline Pte offers Rs.3,100 per share t... [Published PharmaBiz - Dec 16 2013]
GSK announces Rs.864 crore fresh investments in... [Published PharmaBiz - Nov 15 2013]
GSK's Synflorix gets positive opinion from CHMP... [Published Pharmaceutical Business Review - Oct 29 2013]
GSK's Synflorix gets positive opinion from CHMP... [Published PharmaBiz - Oct 28 2013]
Fact Sheet for GlaxoSmithKline Pharmaceuticals Ltd [Published Able2Act - May 06 2008]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 18 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.